$IOVA 🫁 How far can we go with “good enough for approval” NSCLC data? What does “good enough” actually look like, and what would extraordinary data look like?
In November 2025, Iovance Biotherapeutics shared what could ultimately prove to be best-in-class NSCLC data. The word
